Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epratuzumab in Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00042913Phase 2Unknown
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- May 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epratuzumab in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Response Rate and Toxicity. Status: unknown.
02
Drugs
epratuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00042913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00042913.